Savara Inc to Post FY2025 Earnings of ($0.43) Per Share, HC Wainwright Forecasts (NASDAQ:SVRA)

Savara Inc (NASDAQ:SVRA) – Investment analysts at HC Wainwright cut their FY2025 earnings estimates for shares of Savara in a research report issued on Thursday, June 27th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings of ($0.43) per share for the year, down from their prior forecast of ($0.38). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Savara’s current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Savara’s FY2026 earnings at ($0.27) EPS, FY2027 earnings at $0.20 EPS and FY2028 earnings at $0.44 EPS.

A number of other research firms also recently weighed in on SVRA. Oppenheimer raised their price target on shares of Savara from $11.00 to $15.00 and gave the stock an “outperform” rating in a research report on Wednesday, June 26th. Guggenheim upped their target price on shares of Savara from $8.00 to $10.00 and gave the company a “buy” rating in a research note on Thursday, June 27th. Evercore ISI reduced their price target on shares of Savara from $10.00 to $7.00 and set an “outperform” rating on the stock in a research report on Thursday, May 16th. Piper Sandler boosted their price objective on Savara from $7.00 to $16.00 and gave the company an “overweight” rating in a report on Monday, March 4th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $8.00 target price on shares of Savara in a report on Monday, May 6th. Six analysts have rated the stock with a buy rating, According to MarketBeat, Savara presently has a consensus rating of “Buy” and a consensus target price of $11.00.

Savara Price Performance

SVRA stock opened at $4.64 on Monday. The stock’s 50 day moving average is $4.30 and its two-hundred day moving average is $4.64. Savara has a 52-week low of $2.93 and a 52-week high of $5.70. The company has a market capitalization of $641.20 million, a PE ratio of -12.54 and a beta of 0.70. The company has a quick ratio of 14.90, a current ratio of 14.90 and a debt-to-equity ratio of 0.22.

Savara (NASDAQ:SVRA) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.01).

Hedge Funds Weigh In On Savara

Several institutional investors have recently made changes to their positions in SVRA. Opaleye Management Inc. bought a new stake in Savara in the 1st quarter valued at about $4,258,000. California State Teachers Retirement System raised its holdings in shares of Savara by 411.0% during the first quarter. California State Teachers Retirement System now owns 75,986 shares of the company’s stock valued at $378,000 after buying an additional 61,117 shares during the last quarter. AWM Investment Company Inc. bought a new stake in shares of Savara during the first quarter valued at approximately $498,000. Janus Henderson Group PLC boosted its position in shares of Savara by 41.1% during the first quarter. Janus Henderson Group PLC now owns 2,563,620 shares of the company’s stock worth $12,754,000 after buying an additional 746,407 shares during the period. Finally, Bain Capital Life Sciences Investors LLC grew its stake in shares of Savara by 2.3% in the first quarter. Bain Capital Life Sciences Investors LLC now owns 14,565,457 shares of the company’s stock worth $72,536,000 after purchasing an additional 332,706 shares in the last quarter. 87.93% of the stock is owned by institutional investors.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.